Management of stage I/II hypopharyngeal cancer.

Acta oto-laryngologica. Supplementum Pub Date : 2010-11-01 DOI:10.3109/00016489.2010.490240

Morimasa Kitamura, Shigeru Hirano, Ichiro Tateya, Shinpei Kada, Seiji Ishikawa, Tomoko Kanda, Shinzo Tanaka, Juichi Ito

{"title":"Management of stage I/II hypopharyngeal cancer.","authors":"Morimasa Kitamura, Shigeru Hirano, Ichiro Tateya, Shinpei Kada, Seiji Ishikawa, Tomoko Kanda, Shinzo Tanaka, Juichi Ito","doi":"10.3109/00016489.2010.490240","DOIUrl":null,"url":null,"abstract":"Conclusions: It is suggested that radiotherapy might be the first choice for stage I/II hypopharyngeal cancer, and that adjuvant treatment might be necessary for stage II patients to prevent distant metastasis.Objectives: To update the therapeutic outcome of early hypopharyngeal cancer.Methods: Twenty-eight patients with stage I/II hypopharyngeal cancer (8 in stage I, 20 in stage II) were treated at Kyoto University Hospital between 1995 and 2007. Of 8 cases in stage I, radiotherapy was applied for 4 cases, and surgical treatment for another 4, while 13 of 20 cases in stage II underwent radiotherapy and the remaining 7 cases underwent surgery.Results: The 5-year cumulative disease-specific survival and larynx preservation rates were 74.6% and 73.2%, respectively. Recurrent tumors were found in two cases in stage I treated by surgery and in five cases in stage II treated with radiotherapy. Two of five recurrent cases in stage II were rescued by salvage surgery. Distant metastasis to the lung appeared in two cases in stage II after initial treatment.","PeriodicalId":7027,"journal":{"name":"Acta oto-laryngologica. Supplementum","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00016489.2010.490240","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta oto-laryngologica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00016489.2010.490240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Conclusions: It is suggested that radiotherapy might be the first choice for stage I/II hypopharyngeal cancer, and that adjuvant treatment might be necessary for stage II patients to prevent distant metastasis.

Objectives: To update the therapeutic outcome of early hypopharyngeal cancer.

Methods: Twenty-eight patients with stage I/II hypopharyngeal cancer (8 in stage I, 20 in stage II) were treated at Kyoto University Hospital between 1995 and 2007. Of 8 cases in stage I, radiotherapy was applied for 4 cases, and surgical treatment for another 4, while 13 of 20 cases in stage II underwent radiotherapy and the remaining 7 cases underwent surgery.

Results: The 5-year cumulative disease-specific survival and larynx preservation rates were 74.6% and 73.2%, respectively. Recurrent tumors were found in two cases in stage I treated by surgery and in five cases in stage II treated with radiotherapy. Two of five recurrent cases in stage II were rescued by salvage surgery. Distant metastasis to the lung appeared in two cases in stage II after initial treatment.

查看原文本刊更多论文

I/II期下咽癌的处理。

结论:放疗可能是I/II期下咽癌的首选，II期患者可能需要辅助治疗以防止远处转移。目的:提高早期下咽癌的治疗效果。方法:1995 ~ 2007年在京都大学医院治疗的I/II期下咽癌患者28例(I期8例，II期20例)。I期8例中放疗4例，手术4例，II期20例中放疗13例，手术7例。结果:5年累积疾病特异性生存率和喉保存率分别为74.6%和73.2%。一期手术治疗复发2例，二期放疗复发5例。5例II期复发病例中有2例通过挽救性手术得以挽救。2例在初始治疗后出现肺远处转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta oto-laryngologica. Supplementum

自引率

0.00%

发文量